Ion Beam Applications (IBA) has released a cyclotron-based integrated proton therapy system with Pencil Beam Scanning (PBS).
IBA said it has submitted the system to the FDA market clearance approval and it expects to offer the system in the United States when the FDA completes its review. Request for market clearance in other countries will be pursued in parallel, as needed, the company added.
Pierre Mottet, CEO, said that PBS technology will allow better dose conformity to the treatment volume.
PBS, once approved, will be one of four treatment models included within the IBA Universal Nozzle, which is designed to deliver the beam in four delivery modes, including single scattering, double scattering and uniform scanning.